Biocon Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Biocon de 47.6% y 13.1% por año respectivamente. Se prevé que el BPA crezca en un 44.5% al año. Se espera que la rentabilidad financiera sea de 5.7% en 3 años.
Información clave
47.6%
Tasa de crecimiento de los beneficios
44.49%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 35.2% |
| Tasa de crecimiento de los ingresos | 13.1% |
| Rentabilidad financiera futura | 5.68% |
| Cobertura de analistas | Good |
| Última actualización | 21 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Artículo de análisis • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Artículo de análisis • Jun 19
Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...Recent updates
Artículo de análisis • May 21
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Actualización de narrativa • May 03
BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside
Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
Actualización de narrativa • Apr 19
BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry
Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.Actualización de narrativa • Apr 05
BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside
Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
Actualización de narrativa • Mar 21
BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals
Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.Actualización de narrativa • Mar 07
BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals
Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.Actualización de narrativa • Feb 21
BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns
Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.Actualización de narrativa • Feb 07
BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns
Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).Actualización de narrativa • Jan 23
BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside
Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).Actualización de narrativa • Jan 09
BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns
Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).Actualización de narrativa • Dec 26
BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns
Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.Artículo de análisis • Dec 25
Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...Actualización de narrativa • Dec 12
BIOCON: Future Share Dilution Risk Will Likely Pressure Returns
Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).Artículo de análisis • Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...Actualización de narrativa • Nov 27
BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks
Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.Artículo de análisis • Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)
The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...Actualización de narrativa • Nov 13
BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance
Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.Actualización de narrativa • Oct 05
Biosimilars Demand Will Unlock Global Market Opportunities
Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.Artículo de análisis • Sep 22
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...Artículo de análisis • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Artículo de análisis • Aug 04
Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now
Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...Artículo de análisis • Jun 19
Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...Artículo de análisis • Jun 18
Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50
The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
Nueva narrativa • Dec 12
Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability
Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2029 | 249,133 | 21,939 | 24,827 | 47,141 | 6 |
| 3/31/2028 | 228,628 | 19,945 | 27,427 | 41,522 | 18 |
| 3/31/2027 | 200,534 | 13,692 | 22,775 | 38,096 | 18 |
| 3/31/2026 | 169,270 | 3,856 | 823 | 19,940 | N/A |
| 12/31/2025 | 168,274 | 6,042 | N/A | N/A | N/A |
| 9/30/2025 | 164,758 | 4,855 | 17,973 | 41,592 | N/A |
| 6/30/2025 | 157,707 | 3,850 | N/A | N/A | N/A |
| 3/31/2025 | 152,617 | 10,133 | 17,179 | 40,612 | N/A |
| 12/31/2024 | 147,618 | 8,043 | N/A | N/A | N/A |
| 9/30/2024 | 148,941 | 14,392 | 21,045 | 40,368 | N/A |
| 6/30/2024 | 147,660 | 15,808 | N/A | N/A | N/A |
| 3/31/2024 | 147,557 | 10,225 | 10,223 | 29,539 | N/A |
| 12/31/2023 | 146,125 | 12,002 | N/A | N/A | N/A |
| 9/30/2023 | 135,999 | 4,984 | -6,241 | 11,717 | N/A |
| 6/30/2023 | 124,573 | 4,197 | N/A | N/A | N/A |
| 3/31/2023 | 111,742 | 4,627 | 1,262 | 18,525 | N/A |
| 12/31/2022 | 98,091 | 3,881 | N/A | N/A | N/A |
| 9/30/2022 | 90,422 | 6,170 | -6,836 | 11,543 | N/A |
| 6/30/2022 | 85,629 | 7,084 | N/A | N/A | N/A |
| 3/31/2022 | 81,840 | 6,484 | -7,482 | 11,766 | N/A |
| 12/31/2021 | 75,800 | 6,727 | N/A | N/A | N/A |
| 9/30/2021 | 72,632 | 6,542 | -6,366 | 12,763 | N/A |
| 6/30/2021 | 71,726 | 6,852 | N/A | N/A | N/A |
| 3/31/2021 | 71,431 | 7,405 | -5,866 | 11,597 | N/A |
| 12/31/2020 | 68,913 | 5,996 | N/A | N/A | N/A |
| 9/30/2020 | 67,571 | 6,362 | -6,576 | 10,484 | N/A |
| 6/30/2020 | 65,796 | 6,870 | N/A | N/A | N/A |
| 3/31/2020 | 63,005 | 7,771 | -5,534 | 12,831 | N/A |
| 12/31/2019 | 63,150 | 8,385 | N/A | N/A | N/A |
| 9/30/2019 | 61,077 | 8,529 | N/A | 14,573 | N/A |
| 6/30/2019 | 58,565 | 9,919 | N/A | N/A | N/A |
| 3/31/2019 | 55,144 | 9,053 | N/A | 11,546 | N/A |
| 12/31/2018 | 51,551 | 8,220 | N/A | N/A | N/A |
| 9/30/2018 | 46,722 | 6,967 | N/A | N/A | N/A |
| 6/30/2018 | 43,198 | 4,108 | N/A | N/A | N/A |
| 3/31/2018 | 41,234 | 3,724 | N/A | 6,621 | N/A |
| 12/31/2017 | 38,792 | 3,695 | N/A | N/A | N/A |
| 9/30/2017 | 38,589 | 4,489 | N/A | N/A | N/A |
| 6/30/2017 | 38,361 | 5,268 | N/A | N/A | N/A |
| 3/31/2017 | 38,911 | 6,121 | N/A | 6,400 | N/A |
| 12/31/2016 | 40,487 | 11,633 | N/A | N/A | N/A |
| 9/30/2016 | 38,110 | 10,961 | N/A | N/A | N/A |
| 6/30/2016 | 36,539 | 9,388 | N/A | N/A | N/A |
| 3/31/2016 | 33,474 | 5,504 | N/A | 3,706 | N/A |
| 12/31/2015 | 32,997 | 7,367 | N/A | N/A | N/A |
| 9/30/2015 | 32,325 | 7,247 | N/A | N/A | N/A |
| 6/30/2015 | 31,528 | 5,207 | N/A | N/A | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (47.6% al año) de BIOCON es superior a la tasa de ahorro (6.9%).
Beneficios vs. Mercado: Se prevé que los beneficios (47.6% al año) de BIOCON crezcan más rápidamente que el mercado Indian (16.3% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de BIOCON crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (13.1% al año) de BIOCON crezcan más rápidamente que los del mercado Indian (10.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 13.1% al año) de BIOCON crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de BIOCON sea baja dentro de 3 años (5.7%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 04:40 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Biocon Limited está cubierta por 39 analistas. 18 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |